Annual report and accounts 2021/22
Working together to drive change for kidney patients.
Change is even more urgent now.
Our chief executive Sandra Currie, looks back on a year when we built back from the toughest of times, re-launched our research programme, innovated and moved forward at pace with our plans.
"While much of the world went back to ‘normal’, the reality for many kidney patients was very different. Covid-19 remains a threat to life for those who are immunosuppressed and have not responded well to vaccinations. The ongoing situation means our work to transform treatments matters even more now. And while the mental health burden of kidney disease was already in our sights, the pandemic made action on this even more urgent."
Our research strategy set out our ambition to continue to fund high quality kidney research, while being a catalyst that triggers kidney research with new investment, new capacity, new ideas and new energy.
Make it count
Discoveries alone cannot end kidney disease. We’re urgently pressing to make sure research progress translates into better care, and that kidney patients have access to the support they need.
Rally for change
We’re uniting the kidney community around our common goals, doing more than ever to get kidney disease on the political agenda and campaigning for better kidney healthcare and investment in research.
Strive for excellence
We are continually improving the way we do things – becoming an organisation that’s always learning, works quickly and enables our people to be at their best so we can end kidney disease.
How did we do in 2021/22?
During a tough year dominated once again by the Covid-19 pandemic, we have worked hard to push forward in every area of our strategy, but we know there is still more to do.
Building on existing partnerships and creating new ones. Maximising opportunities to increase positive change on kidney health. Focusing our increased investment in research, awareness raising and sustainable income generation.